South Korea's government has stepped in and offered $7.3 million to G-treeBNT to assist the local company in its joint venture with U.S. drugmaker RegenRx Biopharmaceuticals to develop a treatment for dry-eye syndrome and neurotrophic keratopathy in America.
Their JV is ReGenTree, and their drug for now is labeled RGN-259/GBT-201. South Korea's government contribution was intended to help make G-treeBNT a global biopharmaceutical company.
The company said ReGenTree has hopes of becoming "an outstanding specialty biopharmaceutical company."
- get the release